Specialty Chemicals

Dongbao Bio-Tech

Dongbao Bio-Tech released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 190.53 M, actual EPS CNY 0.0306

Dongbao Bio-Tech FY2026 Q1 Earnings Release on April 24 After-Market (BJT)

Dongbao Bio-Tech released FY2025 earnings on March 29 After-Market (BJT), actual revenue CNY 745.31 M, actual EPS CNY 0.0868

Dongbao Bio-Tech released FY2025 Q4 earnings on March 29 After-Market (BJT), actual revenue CNY 212.51 M, actual EPS CNY 0.0097

Dongbao Bio-Tech FY2025 Earnings Release Scheduled for March 30, 2026 After-Market BJT

Dongbao Bio-Tech released FY2025 9 Months Earnings on October 28 After-Market (BJT), actual revenue CNY 532.8 M, actual EPS CNY 0.0762

Dongbao Bio-Tech released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 163.74 M, actual EPS CNY 0.0183

Dongbao Bio-Tech to Release FY2025 Q3 Earnings on October 29 After-Market (BJT)

Dongbao Bio-Tech released FY2025 Semi-Annual Earnings on August 28 After-Market BJT, with actual revenue of CNY 369.06 M and EPS of CNY 0.0579

Dongbao Bio-Tech released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 181.02 M, actual EPS CNY 0.0281

Dongbao Bio-Tech to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Eastbon Biologic's Bone Collagen Vitamin C Powder Completes Domestic Health Food Registration

Dongbao Biotech Announces 2024 Dividend Distribution Plan

Tongbao Biologics Revenue and Net Profit Down in Q1 2025

Dongbao Bio-Tech released FY2025 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 188.03 M, actual EPS CNY 0.0297

Dongbao Bio-Tech released FY2024 earnings on April 23 After-Market (BJT), actual revenue CNY 884.93 M, actual EPS CNY 0.1329

Dongbao Bio-Tech released FY2024 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 251.82 M, actual EPS CNY 0.0304

Dongbao Bio-Tech to Release FY2025 Q1 Earnings on April 24 After-Market BJT

Dongbao Bio-Tech to Release FY2024 Annual Earnings on April 24 After-Market BJT

Dongbao Bio Secretary Responds to Investor Inquiry About Impact of US Tariffs

Ordinary dividend (cash)

Ex Date: 2026.05.27, Cash dividend 0.012 CNY

159837

516930

300239

516500

159849

CS精准医

JingTai Technology has reached a collaboration with YaoTang Bio to innovate and develop AI messenger mRNA drugs, focusing on mRNA drugs and CAR-T therapies, and building an AI-driven mRNA experimental screening platform. The two parties will integrate AI predictive design with experimental validation to improve research and development efficiency and success rates, optimizing the expression efficiency and stability of mRNA sequences. It is expected that this platform can be expanded to more complex disease application scenarios

AASTOCKS

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

JingTai Technology and YaoTang Bio have reached a collaboration for the innovative research and development of AI messenger mRNA drugs

002582

300741

603231

002481

In the morning session, the plant-based meat concept was active, with SHUANGTA FOOD hitting the daily limit, and Solbar, Dongbao Bio-Tech, HAOXIANGNI, and Huabao Limited following suit

Zhitong

HAOXIANGNI

Huabao Limited

Solbar

SHUANGTA FOOD

The concept of artificial meat is active at the beginning of trading, SHUANGTA FOOD hits the limit up

Dongbao Bio-Tech announced that it is expected to trigger the condition for the downward adjustment of the conversion price of the "Dongbao Convertible Bond." From September 17 to September 30, 2025, the closing price of the company's stock has been below RMB 6.63 per share for 90% of the ten trading days. The total amount of this convertible bond issuance is RMB 455 million, listed on August 18, 2023, with a conversion period from February 5, 2024, to July 30, 2029. If the adjustment condition is triggered, the board of directors will decide whether to propose an adjustment plan and submit it for shareholder meeting review, reminding investors to pay attention to risks

Dongbao Bio-Tech: "Dongbao Convertible Bonds" are expected to trigger conditions for a downward adjustment of the conversion price

Dongbao Bio-Tech released its semi-annual report for 2025, with operating revenue of 369 million yuan, a year-on-year decrease of 16.93%; net profit attributable to the parent company was 36.9673 million yuan, a year-on-year decline of 28.00%; net profit excluding non-recurring gains and losses was 33.4351 million yuan, a year-on-year decrease of 27.41%; basic earnings per share were 0.0629 yuan

Dongbao Bio-Tech released its performance for the first half of the year, with a net profit attributable to the parent company of 36.9673 million yuan, a decrease of 28.00%

Dongbao Bio-Tech announced that the company's "Beiyou Mianpai Collagen Protein Vitamin C Powder" product has recently completed the registration work for domestic health food and has obtained the domestic health food registration certificate issued by the State Administration for Market Regulation. This product has health functions that help enhance immunity, with registration number Guo Shi Jian Zhu G20250138, valid until April 29, 2030

Dongbao Bio-Tech: "Beiyou Mian Brand Collagen Protein Vitamin C Powder" product has obtained the domestic health food registration certificate

Dongbao Bio-Tech released its 2024 annual report, with operating revenue of 885 million yuan, a year-on-year decrease of 9.19%; net profit attributable to shareholders was 85.9827 million yuan, a year-on-year decrease of 28.28%; net profit excluding non-recurring gains and losses was 79.0893 million yuan, a year-on-year decrease of 28.17%; basic earnings per share were 0.1448 yuan/share. The company plans to distribute a cash dividend of 0.25 yuan (tax included) for every 10 shares

Dongbao Bio-Tech released its 2024 annual performance, with a net profit attributable to the parent company of 85.9827 million yuan, a year-on-year decrease of 28.28%

Dongbao Bio-Tech released its Q1 2025 performance report, with operating revenue of 188 million yuan, a year-on-year decrease of 22.23%; net profit attributable to the parent company of 19.0448 million yuan, a year-on-year decrease of 26.64%; net profit excluding non-recurring gains and losses of 17.7617 million yuan, a year-on-year decrease of 24.81%; basic earnings per share of 0.0323 yuan/share

Dongbao Bio-Tech released its first-quarter performance, with a net profit attributable to the parent company of 19.0448 million yuan, a year-on-year decrease of 26.64%

605296

Wind data shows that on February 20th, 10 listed companies repurchased shares, among which Shennong Group had the highest repurchase amount of 40 million yuan, repurchasing 1.54 million shares, Dongbao Bio-Tech repurchased 36.44 million yuan, repurchasing 6.65 million shares, and Kaletra repurchased 34.95 million yuan, repurchasing 870,000 shares

Shennong Group

Colorlight

10 listed companies' stocks were repurchased, with Shennong Group having the highest repurchase amount

603658

603111

300298

000503

Yesterday, 18 companies announced stock repurchase plans, among which 3 companies disclosed their repurchase plans for the first time, 4 companies reported implementation progress, and 11 companies have completed their repurchases. In the repurchase plans, Sinocare, Ruoyu Chen, and CHINA REFORM HEALTH had the highest amounts, at 300 million yuan, 200 million yuan, and 636,500 yuan, respectively. In terms of implementation progress, Kalet, Dongbao Bio-Tech, and Yachuang Electronics had the highest repurchase amounts, at 43.1021 million yuan, 40.1431 million yuan, and 4.6771 million yuan, respectively. Among those that have completed repurchases, Autobio, Shui Jing Fang, and KN had the highest amounts, at 445 million yuan, 125 million yuan, and 100 million yuan, respectively

Autobio

Sinocare

CHINA REFORM HEALTH

SCSF

Overview of A-share Stock Buybacks: 18 Companies Disclosed Buyback Progress Yesterday

Dongbao Bio-Tech is currently down 6.5% at HKD 5.3, with a total market value of HKD 3.16 billion. In terms of news, due to violations in fundraising management, the company has consecutively received warning letters and regulatory letters from the Inner Mongolia Securities Regulatory Bureau and the Shenzhen Stock Exchange. Behind a series of violations, Dongbao Bio-Tech's financial situation is also concerning. In the first three quarters of 2024, the company's operating income decreased by 13.82% year-on-year, and the net profit attributable to the parent company fell by 30.43%, with cash flow from operating activities plummeting by over 70%

Dongbao Bio-Tech fell 6.5% due to fundraising management violations receiving "double letters"

Dongbao Bio-Tech(300239.SZ)